- Home
- PRLD vs ENTX Comparison
PRLD vs ENTX Comparison
Compare PRLD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | ENTX |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 74.7M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRLD | ENTX |
|---|---|---|
| Price | $3.60 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 304.4K | 147.2K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $12,140,000.00 | $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.97 |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.61 | $1.00 |
| 52 Week High | $4.19 | $3.22 |
Technical Indicators
Market Signals| Indicator | PRLD | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.26 | 53.08 |
| Support Level | $0.99 | $1.45 |
| Resistance Level | $4.19 | $1.65 |
| Average True Range (ATR) | 0.37 | 0.13 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 96.86 | 66.67 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.